Phenoxyalkylamine derivatives useful as opioid δ receptor agonists
A medicament useful for preventive and/or therapeutic treatment of nerve system diseases which comprises, as an active ingredient, a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof: wherein, X represents a group represented by the following general formula (II), (III), (IV), (V), or (VI), “A” represents a saturated or unsaturated 3- to 6-membered carbocyclic group and the like, “B” represents CH 2 and the like, “n” represents 0 to 2, R 1 represents a hydrogen atom, a halogen atom and the like, R 2 , R 3 , and R 7 to R 14 represent a hydrogen atom, a lower alkyl group which may be substituted and the like, R 4 represents a hydrogen atom, a lower alkyl group which may be substituted and the like, R 5 represents a hydrogen atom, a halogen atom and the like, R 6 represents a saturated or unsaturated monocyclic or bicyclic carbocyclic group and the like, and R 5 and R 6 , R 7 and R 8 , R 9 and R 10 , or R 11 and R 12 may bind to each other to form a cyclic structure.
1. A compound represented by the following formula (I) or a salt thereof:
wherein, X represents the following group (II), (III), (IV), (V), or (VI),
“A” represents a saturated or unsaturated 6-membered carbocyclic group selected from the group consisting of benzene and cyclcohexane,
“B” represents —CH 2 — or a single bond,
“n” represents 0, 1 or 2,
R 1 represents a hydrogen atom, a halogen atom, a lower alkyl group which may be substituted, a lower alkenyl group which may be substituted, a lower alkoxy group which may be substituted, a hydroxy group, a cyano group, an amino group, a N,N-di(lower alkyl)amino group, a N,N-di(substituted lower alkyl)amino group, a nitro group, a carbamoyl group, a N,N-di(lower alkyl)carbamoyl group, a N,N-di(substituted lower alkyl)carbamoyl group, a carboxyl group, a lower alkoxycarbonyl group which may be substituted or a lower alkylcarbonyl group which may be substituted,
R 2 , R 3 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , and R 14 independently represent a hydrogen atom, a lower alkyl group which may be substituted or a lower alkenyl group which may be substituted,
R 4 represents a hydrogen atom, a lower alkyl group which may be substituted, a lower alkenyl group which may be substituted, or a lower alkoxy group which may be substituted,
R 5 and R 6 bind to each other to represent the following group (VIII) or (XVI):
wherein, R 17 or R 26 represents a hydrogen atom, a lower alkyl group which may be substituted, or a lower alkenyl group which may be substituted, and
R 18 or R 27 represents a hydrogen atom, a halogen atom, a lower alkyl group which may be substituted, a lower alkenyl group which may be substituted, a lower alkoxy group which may be substituted, a hydroxy group, a cyano group, an amino group, a N,N-di(lower alkyl)amino group, a N,N-di(substituted lower alkyl)amino group, a nitro group, a carbamoyl group, a N,N-di(lower alkyl)carbamoyl group, a N,N-di(substituted lower alkyl)carbamoyl group, a carboxyl group, a lower alkoxycarbonyl group which may be substituted, or a lower alkylcarbonyl group which may be substituted.
2. The compound or a salt thereof according to claim 1 , wherein X represents the group (II), (III), (V), or (VI),
“A” is a ring selected from the group consisting of benzene and cyclohexane,
“B” represents —CH 2 — or a single bond,
“n” represents 0, 1, or 2,
R 1 represents a hydrogen atom or a lower alkoxy group,
R 2 , R 3 , R 7 , R 8 , R 9 , R 10 , R 13 , and R 14 each independently represent a hydrogen atom or a lower alkyl group which may be substituted,
R 4 represents a hydrogen atom or a lower alkyl group which may be substituted.
3. The compound or a salt thereof according to claim 1 , wherein X represents the group (II).
4. A pharmaceutical composition, said pharmaceutical composition comprising at least one compound of formula (1) according to claim 1 , and a pharmacologically acceptable salt thereof as an active ingredient.
5. The pharmaceutical composition according to claim 4 , wherein the composition further comprises one or more pharmaceutical additives.
6. The pharmaceutical composition according to claim 4 , which has affinity for an opioid δ receptor.
7. A method for therapeutic treatment of a central nerve system disease selected from the group consisting of schizophrenia, depression, cerebral apoplexy, epilepsy, Alzheimer's disease and Parkinson's disease, which comprises administering a therapeutically effective amount of at least one compound according to claim 1 and a pharmacologically acceptable salt thereof to a mammal.
8. A method for therapeutic treatment of pain in diseases of the peripheral nerve system, which comprises administering a therapeutically effective amount of at least one compound according to claim 1 and a pharmacologically acceptable salt thereof to a mammal.
9. The method according to claim 7 , wherein the mammal is a human.
10. The method according to claim 8 , wherein the mammal is a human.